Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN – Get Rating) was the recipient of a large increase in short interest during the month of May. As of May 31st, there was short interest totalling 39,900 shares, an increase of 250.0% from the May 15th total of 11,400 shares. Currently, 0.3% of the company’s shares are sold short. Based […]
Eledon Pharmaceuticals (NASDAQ:ELDN – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Wednesday, Zacks.com reports. According to Zacks, “Eledon Pharmaceuticals Inc. is a clinical stage biotechnology company. It develop treatments for an organ or cell-based transplant, and for people […]
Analysts at Cantor Fitzgerald initiated coverage on shares of Eledon Pharmaceuticals (NASDAQ:ELDN – Get Rating) in a research report issued on Friday, FinViz reports. The firm set an “overweight” rating and a $15.00 price target on the stock. ELDN has been the topic of several other reports. HC Wainwright reaffirmed a “buy” rating and issued […]
Eledon Pharmaceuticals (NASDAQ:ELDN – Get Rating)‘s stock had its “overweight” rating reissued by stock analysts at Cantor Fitzgerald in a note issued to investors on Tuesday, Zacks.com reports. Several other analysts have also issued reports on the company. Zacks Investment Research upgraded Eledon Pharmaceuticals from a “sell” rating to a “hold” rating in a research […]
Equities analysts expect Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN – Get Rating) to post earnings of ($0.74) per share for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Eledon Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.74) and the lowest estimate coming in at ($0.92). The business is expected to […]